Rivus Pharmaceuticals' HU6 Achieves Key Weight Loss Goal in Phase 2a Heart Failure Study

The Phase 2a HuMAIN clinical study of HU6, a controlled metabolic accelerator (CMA), in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) has been announced by Rivus Pharmaceuticals Inc. With HU6 producing a statistically significant weight decrease, the trial's primary goal of weight loss was achieved. At the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Atlanta, findings from the HuMAIN research will be presented. The goal of the study is to lower body fat while maintaining lean muscle mass, especially in the elderly and frail patient group. The HuMAIN data reinforces the use of HU6 in a variety of cardiometabolic disorders with substantial morbidity and supports its potential as the first disease-modifying medication for HFpEF by allowing fat-specific weight reduction while maintaining muscle.

Many secondary effectiveness and pharmacodynamic objectives were satisfied by the trial, and HU6 was shown to be safe and well-tolerated in patients using numerous concurrent drugs and co-morbidities. In 2025, Rivus plans to collaborate with health authorities on a Phase 3 research pertaining to HFpEF associated with obesity. Furthermore, patient enrolment in the Phase 2 M-ACCEL study of HU6 in individuals with metabolic dysfunction-associated steatohepatitis (MASH) is already complete.